# Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

> **NCT04768491** · — · UNKNOWN · sponsor: **Peking Union Medical College** · enrollment: 82 (estimated)

## Conditions studied

- EGFR Activating Mutation
- NSCLC Stage IV
- NSCLC Stage IIIB
- NSCLC, Recurrent

## Interventions

- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT04768491
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-10-31
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04768491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04768491, "Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04768491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*